Back-to-Back with Cancer Immunotherapeutics Conference

Overview

Attacking cancer cells on the molecular level is a new therapeutic approach in cancer treatment with a tremendous amount of promise. Many hurdles still limit the overall success of developing drugs that interfere with carcinogenesis.

Different strategies are being pursued and some of the most promising, such as signal-transduction inhibitors, apoptosis-inducing substances, cell growth inhibitors, cancer vaccines and screening and profiling technologies will be discussed in this inaugural conference.

Important questions will be addressed such as: how to identify new targets, how to increase the effectiveness and specificity of new compounds, how to lower toxic side effects, how to validate specific assays, which targets are active in which group of patients and how to predict the responsiveness.

Don't Miss these Back to Back Events offering....

	Sessions on….  Immunogenicity/ Immunomodulation, All about...Kines, Dendritic Cells, Radiopharmaceuticals, Antibodies, Using Phage Display, Technological Progress, Anti – Angiogenesis, HDAC, Signal Transduction, Personalized Immunotherapy and Small Molecule Therapeutics
	Two Networking Luncheons....  Sponsored by CHI
	See the Latest Products and Services in the Exhibit Hall
	Present a Scientific Poster..... & Save $50
	Poster Snapshots.... Several Posters Presenters will be selected to present a brief oral presentation of their work
	Kick-Off Keynote.... The Use of Cancer Vaccines in Combinatorial Therapies Dr. Jeffrey Schlom, Chief, Laboratory of Tumor Immunology and Biology,  National Cancer Institute, NIH
	Keynote Presentation Immune Monitoring Dr. Rafick-Pierre Sékaly, Professor, Laboratory of Immunology, Unversity de Montreal; Scientific Director, CANVAC
	Featured Presentation.... Funding Opportunities for Preclinical Research at the National Cancer Institute Dr. Min Song, Program Director, Division of Cancer Treatment and Diagnosis,  National Cancer Institute, NIH
	Panel Discussion..... Current Bottlenecks in Targeted Cancer Therapeutics

For sponsorship/exhibit information, please contact:
Suzanne Carroll, Manager, Business Development
Phone: 781-972-5452 • E-mail: scarroll@healthtech.com